Clinical efficacy of rabeprazole versus omeprazole in the treatment of Helicobacter pylori-induced duodenal ulcer
Objective To investigate the clinical efficacy of rabeprazole versus omeprazole in the treatment of Helicobacter pylori(Hp)-induced duodenal ulcer.Methods One hundred patients with Hp-induced duodenal ulcer treated in our hospital from September 2020 to September 2023 were randomly assigned in 1:1 ratio to omeprazole(control group)or rabeprazole(study group).The aim was to compare ulcer healing rate,Hp negative rate,symptoms scores,H+-K+-ATPase activity,intragastric pH,inflammatory factor level,incidence of adverse reactions.The curative effect was assessed.Results None of the curative efficacy differed significantly between groups(P＞0.05).The ulcer healing rate and Hp negative rate were significantly higher in the study group than in the control group(P＜0.05).After treatment,the disorder symptoms scores in the both groups were significantly decreased(P＜0.05),which decreased notably in the study group compared to the control group(P＜0.05).After treatment,significantly decreased H+-K+-ATPase activity,and increased intragastric pH were detected in the study group than those before treatment(allP＜0.05),with between groups significant differences(all P＜0.05).The high-sensitivity C-reactive protein(hs-CRP),tumour necrosis factor alpha(TNF-α),interleukin 6(IL-6)in the both groups were significantly decreased(P＜0.05),the decrease in the study group was more common than the control group(P＜0.05).There were no between groups significant differences in the incidence of adverse reactions including dry mouth,rash,headache,diarrhea,dizziness(P＞0.05).Conclusion Rabeprazole has better therapeutic effect compared to omeprazole in patients with Hp-induced duodenal ulcer,it can reduce H+-K+-ATPase activity,increase intragastric pH,better correct abnormal inflammatory factor levels,rapidly improve disorder symptoms,and with higher effectiveness and safety,which is worthy of clinical priority.
万方数据
维普
